Johnson & Johnson rose 42.7% in a year. Merck rose 67.7%.

Same industry

JNJ against four drug peers, a year at 100

JNJ is up 42.7% in a year. Merck is up 67.7% and Eli Lilly 52.5%. Of these four, AbbVie (+30.5%) and Abbott (−13.4%) did less. Weekly closes, Nov 7, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

JNJ +42.7%. Merck +67.7%, Eli Lilly +52.5%, AbbVie +30.5%, Abbott −13.4%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in JNJ’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

JNJ: stories, the record and filings →